# Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission

> **NCT06669143** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 19 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT06669143
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11
- **Primary completion:** 2026-11
- **Final completion:** 2027-12
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06669143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06669143, "Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT06669143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*